Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Progressive immune dysfunction with advancing disease stage in renal cell carcinoma

Cancer Cell(2021)10.1016/j.ccell.2021.02.013Source: DataRank Database

Progressive immune dysfunction with advancing disease stage in renal cell carcinoma is a research paper published in Cancer Cell (2021). On theSindex it has a DataRank of 9.5. It has been cited 526 times, with 200 citing works in its 1-hop citation network.

N/A

9.5DataRank · unranked

Scored on demand from live citation data

Open Access526 citations · 200 citing works in its network

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (48 grants)Impact (FWCI 33.32)OA: bronzeTopics (45)Linked Datasets (25)DataCite Reuse (25)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 10%Citation Network 90%

Base Score Contribution

0.940

From this paper's citation signal

Citation Network Contribution

8.5

From 200 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 200 citers.

Seeing the forest for the trees—single-cell atlases link CD8+ T cells and macrophages to disease progression and treatment response in kidney cancer
Cancer Cell202126 citations7 referencesContributes 0.471
C‐reactive protein flare‐response predicts long‐term efficacy to first‐line anti‐PD‐1‐based combination therapy in metastatic renal cell carcinoma
Clinical & Translational Immunology202127 citations26 referencesContributes 0.128
FKBP10 promotes clear cell renal cell carcinoma progression and regulates sensitivity to the HIF2α blockade by facilitating LDHA phosphorylation
Cell Death and Disease202457 citations32 referencesContributes 0.127
C‐reactive protein flare‐response predicts long‐term efficacy to first‐line anti‐PD‐1‐based combination therapy in metastatic renal cell carcinoma
OPen Access Repositorium der Universität Ulm (OPARU) (Ulm University)202123 citations26 referencesContributes 0.122
KLRG1 marks tumor-infiltrating CD4 T cell subsets associated with tumor progression and immunotherapy response
Journal for ImmunoTherapy of Cancer202321 citations26 referencesContributes 0.119

Authors (35)

Kelly Street ORCID,Kelly P. Burke ORCID,David L. Cookmeyer,Thomas Denize ORCID,Christina B. Pedersen ORCID

Live enrichment

PubMed:33711273 PMC:PMC8138872 OpenAlex:https://openalex.org/W3135213711

National Institute of General Medical Sciences

Grant: 5R01GM083084

National Institute of General Medical Sciences

Grant: 5R35GM131802

Dermatology Foundation

Grant: P50CA101942-15

National Human Genome Research Institute

Grant: 5R01HG009446

Danmarks Frie Forskningsfond

Grant: 8048-00078B

Dana-Farber/Harvard Cancer Center

Grant: NCI P50-CA101942-12

Dana-Farber/Harvard Cancer Center

Grant: NCI P50CA101942

Dana-Farber/Harvard Cancer Center

Grant: P30CA006516

Dana-Farber Cancer Institute

Grant: NCI-SPORE- 2P50CA101942-11A1

Dana-Farber Cancer Institute

Grant: R50CA251956

Dana-Farber Cancer Institute

Grant: R21 CA216772-01A1

Conquer Cancer Foundation

Grant: R35GM131802

Conquer Cancer Foundation

Grant: R50RCA211482

U.S. Department of Defense

Grant: U24 CA224331

U.S. Department of Defense

Grant: NCI- 1RO1CA155010

NCI NIH HHS

Grant: R50 CA211482

NHGRI NIH HHS

Grant: U24 HG009446

NCI NIH HHS

Grant: P50 CA101942

NCI NIH HHS

Grant: R21 CA216772

NIGMS NIH HHS

Grant: R01 GM083084

NCI NIH HHS

Grant: T32 CA009172

NCI NIH HHS

Grant: R01 CA155010

Astellas Pharma US

Eli Lilly and Company

Genentech

GlaxoSmithKline

Merck

National Cancer Institute

Exelixis

Fondation de France

G. Harold and Leila Y. Mathers Foundation

Gilead Sciences

National Institutes of Health

Celldex Therapeutics

Eisai

Parker Institute for Cancer Immunotherapy

Roche

Bristol-Myers Squibb

Chinook Therapeutics

EMD Serono

Kay Kendall Leukaemia Fund

BioMarin Pharmaceutical

Harvard Medical School

Novartis

American Association for Cancer Research

AstraZeneca

Leukemia and Lymphoma Society

Pfizer

FWCI

33.32

Citation Percentile

1.0%

Citation Trend

2021

2022

2023

2024

2025

2026

bronzeLicense: http://www.elsevier.com/open-access/userlicense/1.0/

journalhttp://www.cell.com/article/S153561082100115X/pdf

publisherhttp://www.cell.com/article/S153561082100115X/pdf

publisherhttps://api.elsevier.com/content/article/PII:S153561082100115X?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S153561082100115X?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.ccell.2021.02.013

Fields of Study

Cancer Immunotherapy and BiomarkersSingle-cell and spatial transcriptomicsImmune cells in cancerBiomarkers, TumorCD8-Positive T-LymphocytesCarcinoma, Renal CellGene Expression Regulation, NeoplasticHumansImmunotherapyKidney NeoplasmsLymphocytes, Tumor-InfiltratingMacrophagesTumor Microenvironment

MeSH Terms

Carcinoma, Renal CellHumansImmunotherapyKidney NeoplasmsMacrophagesBiomarkers, TumorGene Expression Regulation, NeoplasticLymphocytes, Tumor-InfiltratingCD8-Positive T-LymphocytesTumor Microenvironment

Keywords

Immune systemImmunotherapyCancer researchTumor microenvironmentClear cell renal cell carcinomaCD8Renal cell carcinomaBiologyT cellMyeloidCytotoxic T cellCellImmunologyCancerMedicineInternal medicineCancer ImmunotherapyCell-cell InteractionTumor-associated MacrophagesSingle-cell Rna SequencingImmune Cell AtlasCd8 T cell Exhaustion

Sustainable Development Goals

SDG 0: Good health and well-being

Additional file 1 of Refining colorectal cancer classification and clinical stratification through a single-cell atlas

10.6084/m9.figshare.19746454.v1figshare

Additional file 1 of Alpha radionuclide-chelated radioimmunotherapy promoters enable local radiotherapy/chemodynamic therapy to discourage cancer progression

10.6084/m9.figshare.21069728.v1figshare

Additional file 1 of Alpha radionuclide-chelated radioimmunotherapy promoters enable local radiotherapy/chemodynamic therapy to discourage cancer progression

10.6084/m9.figshare.21069728figshare

Additional file 1 of Spatial heterogeneity of tumor microenvironment influences the prognosis of clear cell renal cell carcinoma

10.6084/m9.figshare.23722287.v1figshare

Additional file 1 of Spatial heterogeneity of tumor microenvironment influences the prognosis of clear cell renal cell carcinoma

10.6084/m9.figshare.23722287figshare

Additional file 2 of Spatial heterogeneity of tumor microenvironment influences the prognosis of clear cell renal cell carcinoma

10.6084/m9.figshare.23722290.v1figshare

Additional file 2 of Spatial heterogeneity of tumor microenvironment influences the prognosis of clear cell renal cell carcinoma

10.6084/m9.figshare.23722290figshare

Additional file 3 of Spatial heterogeneity of tumor microenvironment influences the prognosis of clear cell renal cell carcinoma

10.6084/m9.figshare.23722293.v1figshare

Additional file 3 of Spatial heterogeneity of tumor microenvironment influences the prognosis of clear cell renal cell carcinoma

10.6084/m9.figshare.23722293figshare

Additional file 4 of Spatial heterogeneity of tumor microenvironment influences the prognosis of clear cell renal cell carcinoma

10.6084/m9.figshare.23722299figshare

Additional file 4 of Spatial heterogeneity of tumor microenvironment influences the prognosis of clear cell renal cell carcinoma

10.6084/m9.figshare.23722299.v1figshare

Additional file 5 of Spatial heterogeneity of tumor microenvironment influences the prognosis of clear cell renal cell carcinoma

10.6084/m9.figshare.23722302.v1figshare

Additional file 5 of Spatial heterogeneity of tumor microenvironment influences the prognosis of clear cell renal cell carcinoma

10.6084/m9.figshare.23722302figshare

Additional file 1 of Inflammatory response-based prognostication and personalized therapy decisions in clear cell renal cell cancer to aid precision oncology

10.6084/m9.figshare.24447532.v1figshare

Additional file 1 of Inflammatory response-based prognostication and personalized therapy decisions in clear cell renal cell cancer to aid precision oncology

10.6084/m9.figshare.24447532figshare

Additional file 1 of A promising natural killer cell-based model and a nomogram for the prognostic prediction of clear-cell renal cell carcinoma

10.6084/m9.figshare.25059456.v1figshare

Additional file 1 of A promising natural killer cell-based model and a nomogram for the prognostic prediction of clear-cell renal cell carcinoma

10.6084/m9.figshare.25059456figshare

Additional file 2 of Single-cell analysis of immune and stroma cell remodeling in clear cell renal cell carcinoma primary tumors and bone metastatic lesions

10.6084/m9.figshare.25101139.v1figshare

Additional file 2 of Single-cell analysis of immune and stroma cell remodeling in clear cell renal cell carcinoma primary tumors and bone metastatic lesions

10.6084/m9.figshare.25101139figshare

Additional file 1 of Fatty acids metabolism affects the therapeutic effect of anti-PD-1/PD-L1 in tumor immune microenvironment in clear cell renal cell carcinoma

10.6084/m9.figshare.26591399.v1figshare